Aventis’ Estorra Rights Acquired By Private Equity Firm In $115 Mil. Deal
Executive Summary
The Paul Royalty Fund II will purchase Aventis' U.S. rights for Estorra for $115 mil., the private equity firm announced Aug. 9
You may also be interested in...
Lunesta Clears FDA; Sepracor Plans 2005 Release Of Depression Data
Sepracor plans to present data from its completed Lunesta (eszopiclone) Phase IIIb/IV trial for the treatment of insomnia in patients suffering from depression in 2005
Lunesta Clears FDA; Sepracor Plans 2005 Release Of Depression Data
Sepracor plans to present data from its completed Lunesta (eszopiclone) Phase IIIb/IV trial for the treatment of insomnia in patients suffering from depression in 2005
Sanofi-Aventis Begins Operations; Markham, Senior Aventis Execs Depart
Sanofi-Aventis is beginning operations as a top 10 pharmaceutical company in the U.S